Burri Sandhya Rani
BACKGROUND AMH would hinder the effect of FSH and participate in the pathogenesis of PCOS. This proof has led to hypothesise that there is a subgroup of women suffering from PCOS who have the excessive levels of AMH and who are the more resistant to gonadotropins therapy. The aim of the study was to evaluate the serum AMH levels in predicting ovarian response in infertile women with PCOS. MATERIALS AND METHODS This study was a prospective study conducted in Laxmi Narasimha Hospital, Warangal Telangana, for a period of 2 years from January 2014 to February 2016. Totally, 200 women who were admitted in infertility clinic and having induction of ovulation by gonadotropins. The patients were divided into two groups- namely, Group A, which included 100 patients who were women with PCOS having anti-Mullerian hormone <7.77 mg/dL, Group B which included 100 patients who were women with PCOS having anti-Mullerian hormone >7.77 mg/dL. RESULTS Body mass index in kg/m2 of 27.3 ± 3.2 in group A, 27.8 ± 1.5 in group B and the ‘p’ value was nonsignificant, duration of infertility in minutes of 8.0 ± 1.8 in group A, 8.4 ± 2.7 in group B and the ‘p’ value was nonsignificant, number of developing follicles at insemination of 3.2 ± 1.4 in group A, 3.7 ± 1.2 in group B and the ‘p’ value was nonsignificant, mean diameter of dominant follicles at insemination of 22.3 ± 1.1 in group A, 21.0 ± 1.8 in group B and the ‘p’ value was nonsignificant. Biochemical pregnancy rates were 4411.2 in group A, 3122.5 in group B, clinical pregnancy rates were 3022.8 in group A and 2478.1 in group B, dose of HMG (IU/cycle) was 658 ± 35.8 in group A and 820.9 ± 54.9 in group B. AMH sensitivity, specificity, PPV, NPV, accuracy and diagnostic odds ratio was 62, 90, 65, 80, 71.8, 18.25, respectively when threshold concentration was 7.77 ng/mL. CONCLUSION In outcome prediction, circulating serum AMH level evaluation for anovulatory women suffering from PCOS before undergoing therapy acts as a helpful tool. It can act in predicting ovarian response in inducing gonadotropins therapy.
